ImmunityBio Securities Fraud Lawsuit
Analysis based on 12 articles · First reported Apr 01, 2026 · Last updated Apr 29, 2026
The market is impacted by the significant drop in ImmunityBio's stock price due to the United States — Food and Drug Administration's Warning Letter and the subsequent securities fraud class action lawsuit. This event highlights regulatory risks and the importance of accurate product claims for biotechnology companies, potentially leading to increased scrutiny of similar firms.
ImmunityBio, a publicly traded company, is facing a securities fraud class action lawsuit filed by Glancy Prongay & Murray on behalf of investors. The lawsuit stems from a Warning Letter issued by the United States — Food and Drug Administration to ImmunityBio, citing inaccurate claims made by its Executive Chairman, Patrick Soon-Shiong, on a podcast regarding the company's lead biologic product, Anktiva. Soon-Shiong allegedly overstated Anktiva's capabilities, claiming it 'can cure and even prevent all cancer.' Following the Bloomberg News report on the Warning Letter on March 24, 2026, ImmunityBio's stock price plummeted by 21.12%, causing significant losses for investors. The lawsuit alleges that ImmunityBio made materially false and misleading statements and failed to disclose adverse facts about its business and prospects.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard